AOU Modena ALS Centre

Our multidisciplinary centre for MND is located in Modena, at the intersection between Northern and Central Italy. Our team follows 250-300 patients/year providing extended care from the diagnosis to more advanced phases of the disease and supports basic and clinical research with an expertise in leading epidemiological studies and phase II clinical trials.
Following a large number of patients from the province and regional surroundings with a wide multidisciplinary team, this center coordinates Emilia Romagna population-based Register for ALS bringing forward epidemiological research. We collaborate with other national and international institutes to develop multicentric projects for clinical research; besides participating to several trials we currently lead three Italian RCT. A neurobiobank allows to store high-quality and deeply phenotyped samples together with a fully equipped laboratory for molecular biology, cell biology and genetics. The center is included in ITALSGEN Consortium for genetic research and actively collaborate with University of Modena on translational ALS projects and on epidemiological studies. The core of our research team is represented by 4 MND consultants, a data manager, 2 research nurses, a biologist; the local Statistics Unit grants full support for data analysis. Other facilities includes a fully equipped clinical neurophysiology laboratory, a neuropsychology unit and 3T GE system MRI.

AOU Modena ALS Centre
Foundation year



Jessica Mandrioli

Principal investigator

Jessica Mandrioli

Contact information

Via Pietro Giardini 1355,
41126 Modena,


Jessica Mandrioli



Website Visit the website


  • Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers. Zucchi E, Bonetto V, Sorarù G, Martinelli I, Parchi P, Liguori R, Mandrioli J. Mol Neurodegener. 2020 Oct 15;15(1):58.
  • The NGS technology for the identification of genes associated with the ALS. A systematic review. Pecoraro V, Mandrioli J, Carone C, Chiò A, Traynor BJ, Trenti T. Eur J Clin Invest. 2020 May;50(5):e13228.
  • A novel p.N66T mutation in exon 3 of the SOD1 gene: report of two families of ALS patients with early cognitive impairment. Martinelli I, Zucchi E, Gessani A, Fini N, Chiò A, Pecoraro V, Trenti T, Mandrioli J. Amyotroph Lateral Scler Frontotemporal Degener. 2020 May;21(3-4):296-300.
  • FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis. Mandrioli J, Amedei A, Cammarota G, Niccolai E, Zucchi E, D’Amico R, Ricci F, Quaranta G, Spanu T, Masucci L. Front Neurol. 2019 Sep 20;10:1021.
  • Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients. Trojsi F, Siciliano M, Femiano C, Santangelo G, Lunetta C, Calvo A, Moglia C, Marinou K, Ticozzi N, Ferro C, Scialò C, Sorarù G, Conte A, Falzone YM, Tortelli R, Russo M, Sansone VA, Chiò A, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Sabatelli M, Riva N, Logroscino G, Messina S, Fasano A, Monsurrò MR, Tedeschi G, Mandrioli J. Front Neurosci. 2019 May 17;13:485.

For other publications, see:

Restricted information

Serving population
Serving population

Modena: 700000; Emilia Romagna: 4500000

Patient resources
Population based register


Clinic based register


Geographically matched controls


Number of skin samples



Type ALS Patients Controls Other
DNA Bank
Serum Bank
RNA Bank
Research activities
Clinical management research


Neuro epidemiology


Neuro physiology


Neuro imaging


Neuro psychology


Neuro pathology








Clinical Trials - Industry sponsored

Name Type Patients
ALXN1210-ALS-308 Phase III randomized, double blind, placebo controlled , multicenter CT 354
RNS60 Phase II randomized, double blind, placebo controlled , multicenter CT 160

Clinical Trials - Investigator initiated

Name Type Patients
RAP-ALS Phase II randomized, double blind, placebo controlled , multicenter CT 63
CO-ALS Phase II randomized, double blind, placebo controlled , multicenter CT 54
FETR-ALS randomized, double blind, controlled, multicenter CT, testing fecal microbiota transplantation in ALS 42